Live Analyst Rating Changes 24956 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Sumant Kulkarni
CG

Sumant Kulkarni

Canaccord Genuity
Wall Street Analyst
★★★☆☆
#1266
on 13Foresight · ranked by our own returns
59%
Success Rate
+3.0%
Average Return
37 of 63 calls profitable · -0.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 59% of Sumant Kulkarni's ratings turned a profit when each position was held for 1 year — averaging +3.0% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

114 Buy 0 Hold 0 Sell
Sumant's Stock Coverage 25 ratings · 2026-08-15
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CMPS
COMPASS Pathways
 Aug 13, 2026 BUY Strong Buy
+65.6% avg upside
20 analysts
$20.00
50.51% Upside
 +1.2% ·
DFTX
Definium Therapeutics
 Aug 13, 2026 BUY Strong Buy
+18.0% avg upside
21 analysts
$64.00
46.76% Upside
 -2.9% ·
STOK
Stoke Therapeutics
 Aug 12, 2026 BUY Strong Buy
+28.0% avg upside
18 analysts
$58.00
87.20% Upside
 -5.2% ·
VYGR
Voyager Therapeutics
 Aug 12, 2026 BUY Strong Buy
+338.6% avg upside
23 analysts
$12.00
276.20% Upside
 +2.2% ·
CRVO
CervoMed
 Aug 12, 2026 BUY Strong Buy
+574.2% avg upside
9 analysts
$18.00
549.81% Upside
 -11.1% ·
HELP
Helus Pharma
 Aug 12, 2026 BUY Strong Buy
+216.0% avg upside
13 analysts
$42.00
265.62% Upside
 +4.3% ·
ACAD
ACADIA Pharmaceuticals
 Aug 12, 2026 BUY Strong Buy
+29.5% avg upside
43 analysts
$36.00
27.70% Upside
 -4.1% ·
ZVRA
Zevra Therapeutics
 Aug 11, 2026 BUY Strong Buy
+94.8% avg upside
15 analysts
$20.00
79.78% Upside
 -1.1% ·
BHVN
Biohaven Ltd.
 Aug 11, 2026 BUY Strong Buy
+56.3% avg upside
25 analysts
$21.00
43.68% Upside
 +1.7% ·
GHRS
GH Research
 Aug 06, 2026 BUY Strong Buy
+34.4% avg upside
12 analysts
$39.00
32.30% Upside
 -3.8% ·
NBIX
Neurocrine
 Aug 03, 2026 BUY Strong Buy
+22.8% avg upside
37 analysts
$210.00
38.53% Upside
 -5.9% ·
BIIB
Biogen
 Jul 30, 2026 BUY Strong Buy
+21.0% avg upside
52 analysts
$248.00
18.63% Upside
 +0.9% ·
MPLT
MapLight Therapeutics, Inc.
 Jul 27, 2026 BUY Strong Buy
+153.2% avg upside
13 analysts
$24.00
108.46% Upside
 +18.7% ·
ATAI
Atai Beckley N.V.
 Jul 17, 2026 BUY Buy
+33.3% avg upside
17 analysts
$8.00
10.32% Upside
 +0.5% ·
CLNN
Clene
 May 15, 2026 BUY Strong Buy
+687.0% avg upside
11 analysts
$50.00
1104.90% Upside
 -42.0% ·
ANVS
Annovis Bio
 Apr 14, 2026 BUY Strong Buy
+1106.2% avg upside
8 analysts
$17.00
834.00% Upside
 +9.2% ·
BTAI
Bioxcel Therapeutics
 Sep 05, 2025 BUY Buy
+1953.2% avg upside
12 analysts
$18.00
1375.44% Upside
 -70.2% ·
TVRD
Tvardi Therapeutics
 Jun 12, 2024 HOLD Buy
+866.8% avg upside
23 analysts
$36.00
1804.80% Upside
 +6.7% ·
QNCX
Quince Therapeutics
 Jan 28, 2022 HOLD Buy
+561.2% avg upside
16 analysts
$12.00
64.32% Downside
 · ·
VTVT
vTv Therapeutics
 Apr 09, 2018 HOLD Strong Buy
+19.7% avg upside
13 analysts
 — -53.7% ·
TEVA
Teva Pharmaceutical
 Jan 31, 2017 BUY Buy
-17.7% avg upside
39 analysts
 — -36.9% ·
VTRS
Viatris
 Nov 09, 2016 BUY Buy
+45.1% avg upside
21 analysts
$53.00
228.06% Upside
 -2.1% ·
AMRX
Amneal Pharmaceuticals
 Nov 07, 2016 SELL Strong Buy
-0.5% avg upside
18 analysts
$19.00
7.60% Upside
 · ·
PRGO
Perrigo Company
 Jun 14, 2016 SELL Buy
+426.8% avg upside
20 analysts
$109.00
748.24% Upside
 +32.6% ·
TSE:BHC
Bausch Health Companies
 Dec 18, 2015 BUY Buy
+544.9% avg upside
29 analysts
$195.00
2071.52% Upside
 · ·
🔒 20 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Sumant Kulkarni — Frequently Asked Questions
How accurate are Sumant Kulkarni's stock ratings?
Based on the calls 13Foresight could measure, about 59% of Sumant's ratings were profitable over a one-year hold, with an average return of +3.0% per rating, or -0.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Sumant ranked on 13Foresight?
Sumant Kulkarni is currently ranked #1266 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Sumant cover?
Sumant most recently has ratings on CMPS, DFTX, STOK, VYGR, CRVO, HELP, ACAD, ZVRA, BHVN, GHRS, NBIX, BIIB and 13 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.